57
Views
3
CrossRef citations to date
0
Altmetric
Letter to the Editor

Potent antiatherosclerotic effects of alogliptin in addition to its potent antidiabetic effects

Pages 121-123 | Published online: 11 May 2012

References

  • Andukuri R Drincic A Rendell M Alogliptin: a new addition to the class of DPP-4 inhibitors Diabetes Metab Syndr Obes 2009 2 117 126 21437125
  • Moritoh Y Takeuchi K Asakawa T Kataoka O Odaka H The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice Eur J Pharmacol 2009 602 448 454 19038243
  • Monami M Lamanna C Desideri CM Mannucci E DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv Ther 2012 29 14 25 22215383
  • Eliasson B Moller-Goede D Eeg-Olofsson K Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia 2012 55 915 925 22237690
  • Ta NN Schuyler CA Li Y Lopes-Virella MF Huang Y DPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient mice J Cardiovasc Pharmacol 2011 58 157 166 21558879
  • Ta NN Li Y Schuyler CA Lopes-Virella MF Huang Y DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERKdependent MMP-1 expression by U937 histiocytes Atherosclerosis 2010 213 429 435 20843518
  • Moritoh Y Takeuchi K Asakawa T Kataoka O Odaka H Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice Br J Pharmacol 2009 157 415 426 19371350